BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Endometriosis and women's health clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for endometriosis: 33 (27 sponsors; 4 newly posted in the last 180 days, 0 stopped in the last 180 days; 3 new-entrant sponsors). Momentum score 12.1, rank 59 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 1, Phase 2 4, Phase 3 4, Phase 4 1, N/A 23.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Sumitomo Pharma Switzerland GmbH | 3 | NA 2, P3 1 | 0 | 1 |
| AbbVie ABBV | 1 | P3 1 | 0 | 0 |
| Hope Medicine (Nanjing) Co., Ltd | 1 | P3 1 | 0 | 0 |
| Kissei Pharmaceutical Co., Ltd. | 1 | P3 1 | 0 | 0 |
| ZIWIG | 3 | NA 3 | 0 | 1 |
| EDAP TMS S.A. FOCL | 2 | NA 2 | 0 | 0 |
| Samphire Group, Inc. | 2 | NA 2 | 1 | 1 |
| Abbott ABT | 1 | NA 1 | 0 | 0 |
| Aesculap AG | 1 | NA 1 | 0 | 1 |
| Antev Ltd. new entrant | 1 | P2 1 | 1 | 0 |
| Arafarma Group, S.A. | 1 | NA 1 | 0 | 0 |
| Aspira Women's Health AWHL | 1 | NA 1 | 0 | 1 |
| Bio Meds Pharmaceutica Ltda | 1 | P4 1 | 0 | 1 |
| Changchun GeneScience Pharmaceutical Co., Ltd. | 1 | P2 1 | 0 | 0 |
| Cycle Therapeutics Ltd | 1 | NA 1 | 0 | 0 |
| Diamens FlexCo | 1 | NA 1 | 0 | 0 |
| Erbe Elektromedizin GmbH | 1 | NA 1 | 0 | 0 |
| Gesynta Pharma AB | 1 | P2 1 | 0 | 0 |
| Hera Biotech, Inc. | 1 | P2 1 | 0 | 0 |
| Hyivy Health Inc | 1 | NA 1 | 0 | 1 |
| Lyv Healthcare | 1 | NA 1 | 0 | 0 |
| Medtronic - MITG MDT | 1 | NA 1 | 0 | 0 |
| Monath Electronic | 1 | NA 1 | 0 | 0 |
| Pearsanta, Inc | 1 | NA 1 | 0 | 0 |
| SWIMS America Corp. new entrant | 1 | NA 1 | 1 | 1 |
New-entrant sponsors: Antev Ltd., SWIMS America Corp..
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Angitia Biopharmaceuticals | NCT06577935 A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS) | Postmenopausal Osteoporosis | active not recruiting | 379 |
| 2027-01 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT07062978 A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia® | Postmenopausal Women With Osteoporosis at High Risk of Fracture | recruiting | 278 |
| 2027-01-03 est. | P2 | Shenzhen Kangzhe Biotechnology Co., Ltd. | NCT07402369 Phase II Study of CMS-D002 Capsule for Uterine Fibroids With Menorrhagia | Uterine Fibroids With Menorrhagia | recruiting | 120 |
| 2027-02 est. | P1/P2 | AbCellera Biologics Inc. ABCL | NCT07118891 Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause | Vasomotor Symptoms Associated With Menopause; Healthy Volunteers | active not recruiting | 136 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-12 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT06671548 Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | Heavy Menstrual Bleeding; Uterine Fibroids | recruiting | 120 |
| 2026-07-30 est. | P2 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | NCT07579936 A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens | Postmenopausal Women With Osteoporosis | recruiting | 200 |
| 2026-06-01 est. | P2/P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT05442827 A Phase II/III Study of Efficacy and Safety of SHR7280 Tablets in Subjects With Menorrhagia With Uterine Fibroids | Uterine Fibroids With Menorrhagia | unknown | 357 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "endometriosis"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.